Dr. Dimitrov and his research group are experts in display/screening/libraries methodologies, antibody engineering, and protein biochemistry, structural biology and computational biology as well as virology, immunology and cancer biology. His major long-term goal is the development of clinically useful therapeutics and vaccines against cancer, HIV-1 and emerging and biodefense-related viruses as well as other related diseases including immune disorders. The biological therapeutics and vaccines are based on human monoclonal antibodies in several formats including full size antibodies typically IgG1s, engineered antibody domains (eAds), chimeric antigen receptors (CARs), bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), bi-specific T-cell engagers (BiTEs) and bi-specific killer-cell engagers (BiKEs).
